Asset profile
PF-06410293
Monoclonal antibody
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
76 competitors in this universe: 11 direct rivals (same mechanism and indication), 16 same-class, 49 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PF-06410293: this drug | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | ||
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | ||
| Infliximab-Qbtx (Ixifi) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P17 | Phase 3 | Monoclonal antibody | TNF-alpha | ||
| SAR441566 | Phase 2 | Small molecule | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha |
…and 61 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.